{"title":"DSEception: a noval neural networks architecture for enhancing pneumonia and tuberculosis diagnosis","authors":"Shengyi Li, Yue Hu, Lexin Yang, Baohua Lv, Xue Kong, Guangliang Qiang","doi":"10.3389/fbioe.2024.1454652","DOIUrl":null,"url":null,"abstract":"BackgroundPneumonia and tuberculosis are prevalent pulmonary diseases globally, each demanding specific care measures. However, distinguishing between these two conditions imposes challenges due to the high skill requirements for doctors, the impact of imaging positions and respiratory intensity of patients, and the associated high healthcare costs, emphasizing the imperative need for intelligent and efficient diagnostic methods.MethodThis study aims to develop a highly accurate automatic diagnosis and classification method for various lung diseases (Normal, Pneumonia, and Tuberculosis). We propose a hybrid model, which is based on the InceptionV3 architecture, enhanced by introducing Deepwise Separable Convolution after the Inception modules and incorporating the Squeeze-and-Excitation mechanism. This architecture successfully enables the model to extract richer features without significantly increasing the parameter count and computational workload, thereby markedly improving the performance in predicting and classifying lung diseases. To objectively assess the proposed model, external testing and five-fold cross-validation were conducted. Additionally, widely used baseline models in the scholarly community were constructed for comparison.ResultIn the external testing phase, the our model achieved an average accuracy (ACC) of 90.48% and an F1-score (F1) of 91.44%, which is an approximate 4% improvement over the best-performing baseline model, ResNet. In the five-fold cross-validation, our model’s average ACC and F1 reached 88.27% ± 2.76% and 89.29% ± 2.69%, respectively, demonstrating exceptional predictive performance and stability. The results indicate that our model holds promise for deployment in clinical settings to assist in the diagnosis of lung diseases, potentially reducing misdiagnosis rates and patient losses.ConclusionUtilizing deep learning for automatic assistance in the diagnosis of pneumonia and tuberculosis holds clinical significance by enhancing diagnostic accuracy, reducing healthcare costs, enabling rapid screening and large-scale detection, and facilitating personalized treatment approaches, thereby contributing to widespread accessibility and improved healthcare services in the future.","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1454652","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundPneumonia and tuberculosis are prevalent pulmonary diseases globally, each demanding specific care measures. However, distinguishing between these two conditions imposes challenges due to the high skill requirements for doctors, the impact of imaging positions and respiratory intensity of patients, and the associated high healthcare costs, emphasizing the imperative need for intelligent and efficient diagnostic methods.MethodThis study aims to develop a highly accurate automatic diagnosis and classification method for various lung diseases (Normal, Pneumonia, and Tuberculosis). We propose a hybrid model, which is based on the InceptionV3 architecture, enhanced by introducing Deepwise Separable Convolution after the Inception modules and incorporating the Squeeze-and-Excitation mechanism. This architecture successfully enables the model to extract richer features without significantly increasing the parameter count and computational workload, thereby markedly improving the performance in predicting and classifying lung diseases. To objectively assess the proposed model, external testing and five-fold cross-validation were conducted. Additionally, widely used baseline models in the scholarly community were constructed for comparison.ResultIn the external testing phase, the our model achieved an average accuracy (ACC) of 90.48% and an F1-score (F1) of 91.44%, which is an approximate 4% improvement over the best-performing baseline model, ResNet. In the five-fold cross-validation, our model’s average ACC and F1 reached 88.27% ± 2.76% and 89.29% ± 2.69%, respectively, demonstrating exceptional predictive performance and stability. The results indicate that our model holds promise for deployment in clinical settings to assist in the diagnosis of lung diseases, potentially reducing misdiagnosis rates and patient losses.ConclusionUtilizing deep learning for automatic assistance in the diagnosis of pneumonia and tuberculosis holds clinical significance by enhancing diagnostic accuracy, reducing healthcare costs, enabling rapid screening and large-scale detection, and facilitating personalized treatment approaches, thereby contributing to widespread accessibility and improved healthcare services in the future.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.